119 related articles for article (PubMed ID: 7908895)
1. Strong uptake of 111In-pentetreotide by an MIBG-negative, xenografted neuroblastoma.
Manil L; Perdereau B; Barbaroux C; Brixy F
Int J Cancer; 1994 Apr; 57(2):245-6. PubMed ID: 7908895
[TBL] [Abstract][Full Text] [Related]
2. Indium-111-pentetreotide scintigraphy in children with neuroblast-derived tumors.
Manil L; Edeline V; Lumbroso J; Lequen H; Zucker JM
J Nucl Med; 1996 Jun; 37(6):893-6. PubMed ID: 8683306
[TBL] [Abstract][Full Text] [Related]
3. Comparison of In-111 pentetreotide, Tc-99m (V)DMSA and I-123 mlBG scintimaging in neural crest tumors.
Limouris GS; Giannakopoulos V; Stavraka A; Toubanakis N; Vlahos L
Anticancer Res; 1997; 17(3B):1589-92. PubMed ID: 9179199
[TBL] [Abstract][Full Text] [Related]
4. In-111 pentetreotide scintigraphy in patients with neuroblastoma. Comparison with I-131 MIBG, N-Myc oncogene amplification, and patient outcome.
Shalaby-Rana E; Majd M; Andrich MP; Movassaghi N
Clin Nucl Med; 1997 May; 22(5):315-9. PubMed ID: 9152532
[TBL] [Abstract][Full Text] [Related]
5. Successful and unsuccessful approaches to imaging carcinoids: comparison of a radiolabelled tryptophan hydroxylase inhibitor with a tracer of biogenic amine uptake and storage, and a somatostatin analogue.
Macfarlane D; Gonin J; Wieland D; Mangner T; Froelich J; Beierwaltes W; Shapiro B
Eur J Nucl Med; 1996 Feb; 23(2):131-40. PubMed ID: 8925846
[TBL] [Abstract][Full Text] [Related]
6. 111In-pentetreotide scintigraphy is superior to 123I-MIBG scintigraphy in the diagnosis and location of chemodectoma.
Muros MA; Llamas-Elvira JM; Rodríguez A; Ramírez A; Gómez M; Arráez MA; Valéncia E; Vílchez R
Nucl Med Commun; 1998 Aug; 19(8):735-42. PubMed ID: 9751927
[TBL] [Abstract][Full Text] [Related]
7. Metaiodobenzylguanidine and somatostatin in oncology: role in the management of neural crest tumours.
Hoefnagel CA
Eur J Nucl Med; 1994 Jun; 21(6):561-81. PubMed ID: 7915987
[TBL] [Abstract][Full Text] [Related]
8. Could somatostatin scintigraphy be superior to MIBG scan in the staging of stage IVs neuroblastoma (Pepper's syndrome)?
Manil L; Edeline V; Michon J; Neuenschwander S; Lequen H; Lavocat C; Zucker JM
Clin Nucl Med; 1996 Jul; 21(7):530-3. PubMed ID: 8818464
[TBL] [Abstract][Full Text] [Related]
9. MIBG and radiolabeled octreotide in neuroendocrine tumors.
Hoefnagel CA
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):137-9. PubMed ID: 9002773
[TBL] [Abstract][Full Text] [Related]
10. Comparison of radiolabeled octreotide and meta-iodobenzylguanidine (MIBG) scintigraphy in malignant pheochromocytoma.
Tenenbaum F; Lumbroso J; Schlumberger M; Mure A; Plouin PF; Caillou B; Parmentier C
J Nucl Med; 1995 Jan; 36(1):1-6. PubMed ID: 7799058
[TBL] [Abstract][Full Text] [Related]
11. Comparison of MIBG and pentetreotide scintigraphy in children with neuroblastoma. Is the expression of somatostatin receptors a prognostic factor?
Kropp J; Hofmann M; Bihl H
Anticancer Res; 1997; 17(3B):1583-8. PubMed ID: 9179198
[TBL] [Abstract][Full Text] [Related]
12. Combined diagnostic imaging with 131I-metaiodobenzylguanidine and 111In-pentetreotide in carcinoid tumours.
Taal BG; Hoefnagel CA; Valdés Olmos RA; Boot H
Eur J Cancer; 1996 Oct; 32A(11):1924-32. PubMed ID: 8943676
[TBL] [Abstract][Full Text] [Related]
13. Ten years of experience with MIBG applications and the potential of new radiolabeled peptides: a personal overview and concluding remarks.
Shapiro B
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):150-5. PubMed ID: 9002776
[TBL] [Abstract][Full Text] [Related]
14. Therapy of neuroendocrine tumors with radiolabeled MIBG and somatostatin analogues.
Wiseman GA; Kvols LK
Semin Nucl Med; 1995 Jul; 25(3):272-8. PubMed ID: 7570046
[TBL] [Abstract][Full Text] [Related]
15. Combined (111)In-pentetreotide scintigraphy and (123)I-mIBG scintigraphy in neuroblastoma provides prognostic information.
Schilling FH; Bihl H; Jacobsson H; Ambros PF; Martinsson T; Borgström P; Schwarz K; Ambros IM; Treuner J; Kogner P
Med Pediatr Oncol; 2000 Dec; 35(6):688-91. PubMed ID: 11107147
[TBL] [Abstract][Full Text] [Related]
16. Comparison of somatostatin analogue and metaiodobenzylguanidine scintigraphy for the detection of carcinoid tumours.
Nocaudie-Calzada M; Huglo D; Carnaille B; Proye C; Marchandise X
Eur J Nucl Med; 1996 Nov; 23(11):1448-54. PubMed ID: 8854840
[TBL] [Abstract][Full Text] [Related]
17. A comparison of targeting of neuroblastoma with mIBG and anti L1-CAM antibody mAb chCE7: therapeutic efficacy in a neuroblastoma xenograft model and imaging of neuroblastoma patients.
Hoefnagel CA; Rutgers M; Buitenhuis CK; Smets LA; de Kraker J; Meli M; Carrel F; Amstutz H; Schubiger PA; Novak-Hofer I
Eur J Nucl Med; 2001 Mar; 28(3):359-68. PubMed ID: 11315605
[TBL] [Abstract][Full Text] [Related]
18. The value of radiolabelled MIBG and octreotide in the diagnosis and management of neuroendocrine tumours.
Kaltsas GA; Mukherjee JJ; Grossman AB
Ann Oncol; 2001; 12 Suppl 2():S47-50. PubMed ID: 11762352
[TBL] [Abstract][Full Text] [Related]
19. Enhanced tumour uptake and in vitro radiotoxicity of no-carrier-added [131I]meta-iodobenzylguanidine: implications for the targeted radiotherapy of neuroblastoma.
Mairs RJ; Russell J; Cunningham S; O'Donoghue JA; Gaze MN; Owens J; Vaidyanathan G; Zalutsky MR
Eur J Cancer; 1995; 31A(4):576-81. PubMed ID: 7576972
[TBL] [Abstract][Full Text] [Related]
20. Targeting of meta-iodobenzylguanidine to SK-N-SH human neuroblastoma xenografts: tissue distribution, metabolism and therapeutic efficacy.
Rutgers M; Buitenhuis CK; Hoefnagel CA; Voûte PA; Smets LA
Int J Cancer; 2000 Aug; 87(3):412-22. PubMed ID: 10897048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]